Antibody Therapeutics for Life

Notices

Press Release

PR Video

Notices


No Title Written by Written date Inquire
41   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine and Dr. Sung Woo Kim, Head of Business Development are attending BIO 2018.   Admin   2019-01-14   686  
40   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at the company presentation session at BIO 2018.   Admin   2019-01-14   653  
39   PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme.   Admin   2019-01-14   2,273  
38   `` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed.   Admin   2019-01-14   829  
37   ``Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2`` is now indexed on PubMed.   Admin   2019-01-14   779  
36   Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at 9TH CLINICAL TRIALS INNOVATION PROGRAMME on April 26-27, 2018.   Admin   2019-01-14   904  
35   Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a keynote presentation at Asia Pharma R&D Leaders Summit 2018 on April 17-18, 2018.   Admin   2019-01-14   649  
34   Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at BOSTON CEO on May 10th, 2018.   Admin   2019-01-14   749  
33   PharmAbcine was introduced today in The South China Morning Post-2018 South Korea Business Report.   Admin   2019-01-14   550  
32   PharmAbcine enters collaboration with MSD focused on clinical evaluation of TTAC-0001 in combination with KEYTRUDA® (pembrolizumab) in recurrent glioblastoma and breast cancer.   Admin   2019-01-14   548